Press Releases | BioLineRx

Date	Title	Additional Formats
20 Nov 2023	BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates	PDF Version
13 Nov 2023	BioLineRx to Report Third Quarter 2023 Results on November 20, 2023	PDF Version
12 Oct 2023	BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment	PDF Version
28 Sep 2023	BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)	PDF Version
19 Sep 2023	BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer	PDF Version
11 Sep 2023	BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma	PDF Version
30 Aug 2023	BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates	PDF Version
22 Aug 2023	BioLineRx to Report Second Quarter 2023 Results on August 30, 2023	PDF Version
17 Jul 2023	BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide	PDF Version
24 May 2023	BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates	PDF Version
17 May 2023	BioLineRx to Report First Quarter 2023 Results on May 24, 2023	PDF Version
25 Apr 2023	BioLineRx Regains Compliance with Nasdaq Minimum Bid Price Requirement	PDF Version
17 Apr 2023	BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma	PDF Version
22 Mar 2023	BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates	PDF Version
15 Mar 2023	BioLineRx to Report 2022 Annual Financial Results on March 22, 2023	PDF Version
06 Mar 2023	BioLineRx Announces Clinical Trial Collaboration with Washington University School of Medicine to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease	PDF Version
04 Jan 2023	BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer	PDF Version